U.S. Metals and Mining Stock News

What Essent Group’s latest quarter means for investors Essent Group (ESNT) just posted first quarter results that topped analyst earnings and revenue expectations, alongside an affirmed US$0.35 quarterly dividend and updates on its growing property & casualty reinsurance platform. See our latest analysis for Essent Group. The earnings beat and reaffirmed dividend have arrived alongside a recent pick up in momentum, with a 1 day share price return of 2.52% and 7 day share price return of...

In early May 2026, Caris Life Sciences reported first-quarter revenue of US$216.17 million versus US$120.92 million a year earlier, with net loss improving to US$0.51 million, while also securing MolDX approval for its Caris ChromoSeq whole genome assay and launching the AI-driven Caris MI Clarity breast cancer prognostic test. Together, these developments highlight Caris’ efforts to broaden its precision oncology portfolio across hematologic malignancies and early-stage breast cancer, while...

Valero Energy (VLO) has just paired a regular quarterly dividend of $1.20 per share with a sharp swing back to profitability in the first quarter, giving investors fresh numbers to reassess the stock. See our latest analysis for Valero Energy. The recent quarterly profit and steady dividend come against a share price of $236.35, with a 90 day share price return of 16.61% and a year to date share price return of 42.97%. The 1 year total shareholder return of 99.87% suggests strong momentum has...

Mondelez International recently reported first-quarter 2026 results, with sales rising to US$10.08 billion and net income increasing to US$560 million, alongside higher basic and diluted earnings per share of US$0.44 from continuing operations. In addition, the company’s chief global inclusion and learning officer is scheduled to speak at the ISG Future Workplace Summit in New York, highlighting how its focus on workforce development and inclusion sits alongside its improving financial...

PACCAR Inc’s board previously approved an increase in its regular quarterly cash dividend from US$0.33 to US$0.35 per share, payable on June 3, 2026, to shareholders of record as of May 13, 2026, while reporting first-quarter 2026 sales of US$6,234.3 million and net income of US$605.3 million. Although revenue declined compared with a year earlier, higher net income, earnings per share growth, and a higher dividend suggest management confidence in the company’s underlying profitability and...

In the past week, BeOne Medicines AG reported first-quarter 2026 results with revenue of US$1,513.44 million and net income of US$227.36 million, raised its full-year 2026 revenue and GAAP operating income guidance, and filed an omnibus shelf registration of up to about US$9.12 billion in various securities. The company also received FDA Priority Review and Breakthrough Therapy Designation for its TEVIMBRA and ZIIHERA combination in HER2-positive gastroesophageal adenocarcinoma, supported by...

In the first quarter of 2026, Phillips 66 reported revenue of US$33.00 billion and net income of US$207 million, with earnings per share from continuing operations of US$0.51, reflecting solid refining margins and improved performance in chemicals and renewable fuels. Analysts highlighted that stronger refining margins and better results in chemicals and renewable fuels underpinned the earnings beat, reinforcing management’s emphasis on an integrated business model, capital discipline, and...

DigitalOcean Holdings (DOCN) has quickly moved back onto investor radar following first quarter 2026 results, higher revenue guidance for 2026 and 2027, and new AI infrastructure launches that have reset expectations for the stock. See our latest analysis for DigitalOcean Holdings. The share price has been on a sharp upswing, with a 30-day share price return of 73.73% and a 90-day share price return of 139.08%. The 1-year total shareholder return of 403.28% highlights how strongly recent...

Nuvation Bio (NUVB) has drawn fresh attention after reporting first quarter revenue of US$83.23 million and a profit of US$5.4 million, alongside new FDA and guideline milestones for its oncology drug IBTROZI. See our latest analysis for Nuvation Bio. The stock has been volatile, with a 1-day share price return of a 4.56% decline following a strong 7-day share price return of 8.09%. The year-to-date share price return of a 43.94% decline contrasts with a very large 1-year total shareholder...

Fortive recently reported first-quarter 2026 results showing revenue of US$1,069.4 million and net income of US$136.4 million, while also boosting its share repurchase authorization to 72,378,691 shares with 20,000,000 shares remaining available. Behind the headlines, management highlighted strong demand in Intelligent Operating Solutions and Advanced Healthcare Solutions, with AI-enhanced and recurring-revenue offerings growing faster than overall sales and supporting the reaffirmed...

Recently, Keysight Technologies reported earnings and guidance that exceeded expectations, supported by broad-based demand in AI infrastructure, aerospace and defense, and semiconductors, while also launching a PCIe 7.0 receiver test solution and deepening its collaboration on electric-vehicle charging standards in China. Together, these developments highlight how Keysight is pairing strong current execution with product and partnership innovation in emerging areas like high-speed computing...

FormFactor (FORM) is back on investors’ radar after first quarter 2026 earnings, with sales of US$226.14 million and net income of US$20.38 million, along with Q2 guidance pointing to record quarterly revenue. See our latest analysis for FormFactor. The strong first quarter and guidance have come alongside sharp share price momentum, with a 30 day share price return of 37.63% and a year to date share price return of 144.43%, while the 1 year total shareholder return is very large. If...

SL Green Realty (SLG) is back in focus after its One Madison Avenue project received the 2026 Urban Land Institute Award for Excellence in Development and reached 100% leasing, alongside flagship peer asset One Vanderbilt. See our latest analysis for SL Green Realty. The award recognition comes as momentum in SL Green Realty’s stock has picked up, with a 6.77% 7 day share price return and a 20.55% 30 day share price return. The 1 year total shareholder return is a 14.13% loss, while the 3...

SPX Technologies (SPXC) drew investor attention after first quarter sales reached US$566.8 million with net income of US$59.9 million, alongside higher full year 2026 revenue guidance in the range of US$2.575 billion to US$2.645 billion. See our latest analysis for SPX Technologies. The latest earnings update and raised 2026 revenue guidance came as the share price has been relatively flat year to date, with a 0.99% share price return. Total shareholder return over the past year is 37.43%,...

In early May 2026, BorgWarner reported first‑quarter 2026 sales of US$3,533 million and net income of US$242 million, while maintaining full‑year guidance that targets net sales of US$14.00–US$14.30 billion and a U.S. GAAP operating margin of 9.7%–9.9%. A wave of recent program wins in electrified and emissions-focused technologies, spanning Asian eMotor awards and a Euro 7 commercial vehicle platform, suggests BorgWarner is deepening its role in next‑generation propulsion across both...

Recent performance and business snapshot Lantheus Holdings (LNTH) has drawn attention after a stretch of strong share price performance, with the stock up over the past week, month and past 3 months, while also showing a double digit 1 year total return. The company develops diagnostic and therapeutic products used in the detection and treatment of heart disease, cancer and other conditions, reporting revenue of US$1,546.178 million and net income of US$279.031 million from its portfolio of...

Arcutis Biotherapeutics (ARQT) is in focus after reporting Q1 2026 revenue of US$105.4 million, a narrowed net loss of US$11.3 million, positive operating cash flow, and reaffirmed full year revenue guidance. See our latest analysis for Arcutis Biotherapeutics. The stock closed at US$20.66 after the results, with a 1-day share price return of -14.52% and a year to date share price return of -28.76%. However, the 1-year total shareholder return is 52.87%, which suggests recent momentum has...

Gilat Satellite Networks (GILT) has attracted fresh attention after announcing two new orders: a multimillion contract with India based Nelco for its SkyEdge IV platform, and a separate US$7 million plus EnduroStream amplifier order linked to the U.S. Department of War. See our latest analysis for Gilat Satellite Networks. At a share price of US$18.84, the stock has had a 40.49% year to date share price return and a 188.96% 1 year total shareholder return. If these contract wins have you...

Vertex Pharmaceuticals (VRTX) is back in focus after Germany’s GKV-Spitzenverband agreed to reimburse CASGEVY, widening access to the gene edited therapy and reinforcing the company’s broader push beyond cystic fibrosis treatments. See our latest analysis for Vertex Pharmaceuticals. Despite strong Q1 results and reaffirmed full year guidance, recent momentum in Vertex’s share price has faded, with a 90 day share price return of an 11.07% decline, while the 5 year total shareholder return of...

Vaxcyte (PCVX) is back in focus after the company reported a first quarter net loss of US$320.62 million, along with updates on its advancing VAX-31 vaccine trials and an upcoming study for VAX-A1. See our latest analysis for Vaxcyte. The stock has given up some ground recently, with a 1 day share price return of 9.84% decline and a 30 day share price return of 15.18% decline. However, the year to date share price return is 10.8% and the 1 year total shareholder return is 63.69%, suggesting...

Ultragenyx Pharmaceutical: Recent Move in Context Ultragenyx Pharmaceutical (RARE) has drawn fresh attention after its recent trading, with the stock closing at US$26.13. Investors are weighing this price against the company’s mixed return profile across the past year and the past 3 months. See our latest analysis for Ultragenyx Pharmaceutical. The recent move to US$26.13 comes after a 12.87% 1 month share price return and a 10.72% year to date share price return, set against a 27.38% 1 year...

Recent performance snapshot Spectrum Brands Holdings (SPB) has drawn attention after a mixed run in the stock, with a 7 day decline and a small drop in the latest session alongside positive returns over the month and past 3 months. Over longer periods, total return over the past year and past 3 years is positive, while the 5 year total return is slightly negative. This gives investors a mixed performance profile to weigh against the company’s fundamentals. See our latest analysis for Spectrum...

How BridgeBio Pharma stock has been trading BridgeBio Pharma (BBIO) has drawn investor attention after a strong 1 year total return of 93.54%. This contrasts with weaker recent trading, with the stock down 6.2% over the past month and 13.79% year to date. See our latest analysis for BridgeBio Pharma. The recent 1 day and 1 month share price declines sit against a much stronger backdrop, with a 1 year total shareholder return of 93.54% and a 3 year total shareholder return above 3x. This...

CVS Health (CVS) delivered first quarter 2026 earnings that came in ahead of expectations across all segments. This prompted higher full year earnings guidance and fresh attention on its pharmacy, insurance and technology plans. See our latest analysis for CVS Health. The 1-month share price return of 11.68% and 90-day share price return of 11.50% suggest momentum has picked up around the recent earnings beat and raised guidance. The 1-year total shareholder return of 33.46% points to a...